Jasper Therapeutics

Jasper Therapeutics

[Jasper Therapeutics @JasperBio]

Jasper is excited to host a key opinion leader webinar on the potential of briquilimab in chronic urticaria. The event will begin at 8:00am EST tomorrow, 10/11. Link to register: https://t.co/JEwNz5f4sQ

[Jasper Therapeutics @JasperBio]

Jasper Therapeutics is pleased to announce that the FDA has accepted our IND application for briquilimab in #ChronicSpontaneousUrticaria. We look forward to initiating our phase 1b/2a study in CSU later this year. Read the full announcement: https://t.co/tutu4nklSn

[Jasper Therapeutics @JasperBio]

Jasper is excited to announce the addition of Patricia Carlos (SVP, Regulatory Affairs and Quality) and Annette Marcantonio (VP, Clinical Operations) to the team! https://t.co/nE3EGBDudj

[Jasper Therapeutics @JasperBio]

Today we announced the first patient dosed in a Phase 1 trial, which is evaluating briquilimab’s therapeutic potential in targeting c-Kit for people with low-risk myelodysplastic syndrome. Read more: https://t.co/79kEEc3ldp #MDS

[Jasper Therapeutics @JasperBio]

Today, we announced the appointment of Dr. Scott Brun to our Board of Directors. His 20+ years of drug development experience makes him an excellent asset as we advance briquilimab in chronic mast cell and stem cell-driven disease. Full announcement: https://t.co/AQcRgJWbnN

[Jasper Therapeutics @JasperBio]

Thrilled to announce Dr. Edwin J. Tucker has joined as our new CMO. An accomplished #biotech and large pharma exec, his expertise will be invaluable as our clinical programs expand. Acting CMO, Dr. Daniel Adelman, will join our Scientific Advisory Board. https://t.co/0iw0YPdqOt

[Jasper Therapeutics @JasperBio]

At Jasper, we believe in the power of diversity and inclusivity. This #PrideMonth, let’s celebrate the LGBTQ+ community by creating a world where everyone can live their lives with love, acceptance, and equal opportunities. 🏳️‍🌈

[Jasper Therapeutics @JasperBio]

This World Blood Cancer Day, we share in bringing awareness to current limited treatment options. We’re joining the fight by exploring how targeting c-Kit may offer a new approach for people with low-to-intermediate risk myelodysplastic syndromes (#MDS). #WBCD

[Jasper Therapeutics @JasperBio]

We recently celebrated the Jasper lab team and the critical role they play in advancing our therapeutic pipeline targeting c-Kit for chronic mast and stem cell diseases. Thank you for your invaluable contributions – you make our work possible! #LabWeek2023 #TheFutureisLab

[Jasper Therapeutics @JasperBio]

Our Senior VP of Research and Translational Medicine, Dr. Wendy Pang, is featured in an @AuthorityMgzine series highlighting inspirational women in STEM and tech. Read the full article to learn about her advice for building a successful career in #biotech: https://t.co/kSZugbaC5u

[Jasper Therapeutics @JasperBio]

Today we announced Dr. Stephen J. Galli as the newest addition to our Scientific Advisory Board. He is a recognized researcher on the biology and pathology of mast cells, and he joins us as we advance our work in targeting c-Kit for #mastcell diseases. https://t.co/uvjTGGT90V

[Jasper Therapeutics @JasperBio]

We are thrilled to announce the appointment of Matt Ford as our new Vice President, Human Resources. We’re excited to welcome him to help further build our Jasper team! https://t.co/w1zcucCDH6

[Jasper Therapeutics @JasperBio]

We’re happy to welcome David Hinds as our Senior Vice President of Development Operations. With 25+ years of experience in operations and clinical program development, his leadership will be instrumental in helping advance our current and future studies. https://t.co/8bR13s4DoY

[Jasper Therapeutics @JasperBio]

Recently, our team came together for a fun night of strikes and bonding over bowling. We’re grateful to team up in and out of the office.

[Jasper Therapeutics @JasperBio]

Join Dr. Wendy Pang at Cantor’s The Future of #Oncology Virtual Symposium. Read more: https://t.co/u9MRzJpYBD $JSPR

[Jasper Therapeutics @JasperBio]

We’re thrilled to welcome Dr. Daniel Adelman as our new Acting Chief Medical Officer! His extensive experience in clinical development of novel therapies for #immunologic diseases will be vital to our team. Read more: https://t.co/9YX1jAXZh4

[Jasper Therapeutics @JasperBio]

Our CEO Ron Martell will present at two upcoming investor conferences this month. Join us at @WilliamBlair’s Innovator Series: What’s Next in Dermatology? and the @Oppenheimer 33rd Annual Healthcare Conference. Learn more here: https://t.co/QAijkT1AdF #OPCOHC2023

[Jasper Therapeutics @JasperBio]

Today we announced 2022 financial results and a business update. Read the details here: https://t.co/7nrae7Rlcv $JSPR

[Jasper Therapeutics @JasperBio]

Today in recognition of International Women’s Day, we asked Jasper SVP Wendy Pang to share what this year’s theme #EmbraceEquity means to her. #IWD2023

[Jasper Therapeutics @JasperBio]

ICYMI: @TargetedOnc interviewed Lori Muffly, MD, about briquilimab data presented at #Tandem23 showing promise for targeting c-Kit in MDS/AML undergoing alloHCT. Read the full interview: https://t.co/ENdZVMlH1k